Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 244

Results For "AP"

7944 News Found

Dr Reddy’s relaunch Naproxen Sodium Tablets in the US
News | August 04, 2021

Dr Reddy’s relaunch Naproxen Sodium Tablets in the US

It is part of the company’s pain/analgesics portfolio of OTC products


Illumina donates US $ I million in sequencing capabilities to BMC in Mumbai
Healthcare | August 04, 2021

Illumina donates US $ I million in sequencing capabilities to BMC in Mumbai

It supports sequencing-based COVID 19 surveillance in India


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Evexia Lifecare to manufacture API of Isometa
News | August 03, 2021

Evexia Lifecare to manufacture API of Isometa

Robust demand for the product across the Middle East, Africa and Latin America


NPPA caps prices on five medical devices effective July 20th 2021
Policy | August 03, 2021

NPPA caps prices on five medical devices effective July 20th 2021

The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers


PI Industries acquires API business of Ind Swift Laboratories
News | August 02, 2021

PI Industries acquires API business of Ind Swift Laboratories

Turnover of API division of ISLL stood at Rs 856.58 crore


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Zydus Cadila receives approval from USFDA for Fulvestrant Injection
News | July 31, 2021

Zydus Cadila receives approval from USFDA for Fulvestrant Injection

The group now has 320 approvals and has so far filed over 400 ANDAs